



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Beck et al.  
Serial No. : 09/902,845  
Cnfrm. No. : 9511  
Filed : July 11, 2001  
For : NOVEL 4-PHENYL SUBSTITUTED  
TETRAHYDROISOQUINOLINES  
THERAPEUTIC USE THEREOF

Examiner  
B.M. Robinson

Art Unit:  
1625

RECEIVED  
JAN 02 2003  
TECH CENTER 1600/2900

**RESPONSE TO RESTRICTION REQUIREMENT**

U.S. Patent and Trademark Office  
P.O. Box 2327  
Arlington, Virginia 22202

Dear Sir:

In response to the November 22, 2002, office action, applicants hereby elect Group I (i.e., claims 1-40) with traverse. For clarification purposes, applicants are electing Group I with the understanding that this invention group is drawn to a compound of Formula IA, IB, IIA, IIB, IIIA, or IIIB, and a method of treating an animal with a pharmaceutical composition comprising said compound, where X is oxygen and where  $R^8+R^9$  or  $R^{10}+R^{11}$  is piperidine.

Nevertheless, applicants submit that it is inappropriate to impose a restriction requirement here, because the various groups of invention identified in the restriction requirement are related to one another and would necessarily require common areas of search and consideration. Accordingly, the restriction requirement should be withdrawn.

As listed below, with respect to claims 1-35 and 38-40, applicants further elect a single species for each of the chemical structural positions (i.e., positions X,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ , and  $R^7$ ) identified by the U.S. Patent and Trademark Office in the pending office action:

<u>Position</u>	<u>Species Elected</u>
X	oxygen
$R^1$	methyl
$R^2$	hydrogen
$R^3$	hydrogen
$R^4$	hydrogen
$R^5$	fluorine
$R^6$	hydrogen
$R^7$	hydrogen

In view of the foregoing, applicants respectfully submit that the claims of Groups I through VI should be examined on the merits at this time.

Respectfully submitted,

Date: December 23, 2002



Michael L. Goldman


Registration No. 30,727

NIXON PEABODY LLP  
Clinton Square, P.O. Box 31051  
Rochester, New York 14603-1051  
Telephone: (585) 263-1304  
Facsimile: (585) 263-1600

**Certificate of Mailing - 37 CFR 1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
U.S. Patent and Trademark Office P.O. BOX 2327  
Arlington, VA 22202, on the date below.

Date

12/23/02   
Jane C. Wirszyła

RECEIVED  
JAN 02 2003  
TECH CENTER 1600/2330



RECEIVED 1625

JAN 02 2003

TECH CENTER 1600/2000

Docket No.: 20011/1381

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Beck et al.

Serial No. : 09/902,845

Cnfrm. No. : 9511


Filed : July 11, 2001


For : NOVEL 4-PHENYL SUBSTITUTED  
TETRAHYDROISOQUINOLINES  
THERAPEUTIC USE THEREOFExaminer:  
B.M. RobinsonArt Unit:  
1625U.S. Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202  
**Box:**

Sir:

Transmitted herewith in the above-identified application are:

- ☒ [X] A Response to Restriction Requirement; and
- ☒ [X] A self-addressed, prepaid postcard for acknowledging receipt.
- ☒ [X] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-1138. **A duplicate copy of this sheet is enclosed.**

Date: December 23, 2002  
Michael L. Goldman  
Registration No. 30,727NIXON PEABODY LLP  
Clinton Square, P.O. Box 31051  
Rochester, New York 14603-1051  
Telephone: (585) 263-1304  
Facsimile: (585) 263-1600

<b>Certificate of Mailing - 37 CFR 1.8(a)</b> I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: U.S. Patent and Trademark Office P.O. BOX 2327 Arlington, VA 22202, on the date below. Date <u>12/23/02</u>  Jane C. Wirszya
---